NASDAQ
187.53USD
-4.64 (-2.41%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
39.9B
P/E
—
EPS
—
Beta
1.38
52W range
34-194.56
Day range
186.23–192.00
Open
191.24
Prev close
192.17
Volume
1.5M
Avg volume
2.7M
Dividend
0.00
IPO
2020-02-13
https://www.newsfilecorp.com/release/307456/ERAS-SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 8/2/2026+0.50
https://www.newsfilecorp.com/release/306151/ERAS-INVESTOR-DEADLINE-APPROACHING-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/24/2026+0.50
https://www.newsfilecorp.com/release/305563/ERAS-CLASS-ACTION-NOTICE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/20/2026+0.30
https://www.newsfilecorp.com/release/304751/ERAS-UPCOMING-DEADLINE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/13/2026
https://www.prnewswire.com/news-releases/erasca-eras-faces-securities-class-action-after-stock-declines-48-on-drug-safety-and-ip-concerns---hbss-302820077.html · 7/8/2026+0.30
https://www.globenewswire.com/news-release/2026/07/06/3322768/32716/en/Erasca-ERAS-Faces-Securities-Class-Action-After-Stock-Declines-48-on-Drug-Safety-and-IP-Concerns-HBSS.html · 7/6/2026+0.20
https://www.newsfilecorp.com/release/303757/ERAS-SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Reminds-Erasca-ERAS-Investors-of-Securities-Class-Action-Lawsuit-Deadline-on-August-10-2026 · 7/4/2026+0.40
https://www.prnewswire.com/news-releases/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss----hbss-302813490.html · 6/29/2026+0.50
https://www.globenewswire.com/news-release/2026/06/25/3317237/32716/en/Erasca-Inc-ERAS-Faces-Securities-Class-Action-Amid-Patient-Death-Intellectual-Property-Questions-2-8-Billion-Market-Cap-Loss-Hagens-Berman.html · 6/25/2026+0.50
https://www.prnewswire.com/news-releases/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss----hbss-302807888.html · 6/23/2026+0.30
https://www.prnewswire.com/news-releases/eras-stockholder-alert-shareholder-rights-law-firm-robbins-llp-reminds-investors-of-the-securities-class-action-lawsuit-against-erasca-inc-302800838.html · 6/16/2026+0.30
https://www.globenewswire.com/news-release/2026/06/15/3312096/3080/en/ERAS-Shareholder-Alert-Erasca-Inc-Securities-Class-Action-Lawsuit-Investors-With-Losses-May-Contact-Levi-Korsinsky.html · 6/15/2026+0.30
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
